{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(20)"],"submitter":["Hawkes EA"],"pubmed_abstract":["<h4>Abstract</h4>Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffective in DLBCL/FL; however, evidence suggests synergy with radiotherapy (RT), but no clear biomarkers. This phase 1 study examined the safety of escalating RT dose and treated volumes with durvalumab (PD-L1 inhibitor) in 34 adults with relapsed/refractory DLBCL and relapsed/refractory FL, and the role of immune-cell subsets on outcomes. Patients received external-beam RT (2.5-30 Gray [Gy], 5 or 10 fractions up to 3 target sites) plus durvalumab from RT day 2, until progression. Novel positron emission tomography (PET) biodistribution studies"],"journal":["Blood advances"],"pagination":["5263-5273"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12552934"],"repository":["biostudies-literature"],"pubmed_title":["T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial."],"pmcid":["PMC12552934"],"pubmed_authors":["Palmer JB","Manos K","Scott AM","Barraclough A","Chong G","Gandhi MK","Smith C","Martynchyk A","Chowdhury R","Scott FE","Hawkes EA","Churilov L","Shortt J","MacManus M","Law SC","Burgess M","Swain F","Keane C","Khor R","Lee ST"],"additional_accession":[]},"is_claimable":false,"name":"T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.","description":"<h4>Abstract</h4>Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffective in DLBCL/FL; however, evidence suggests synergy with radiotherapy (RT), but no clear biomarkers. This phase 1 study examined the safety of escalating RT dose and treated volumes with durvalumab (PD-L1 inhibitor) in 34 adults with relapsed/refractory DLBCL and relapsed/refractory FL, and the role of immune-cell subsets on outcomes. Patients received external-beam RT (2.5-30 Gray [Gy], 5 or 10 fractions up to 3 target sites) plus durvalumab from RT day 2, until progression. Novel positron emission tomography (PET) biodistribution studies","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-05T05:17:29.421Z","creation":"2026-06-04T03:06:03.344Z"},"accession":"S-EPMC12552934","cross_references":{"pubmed":["40540795"],"doi":["10.1182/bloodadvances.2025016505"]}}